Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dainippon Sumitomo's Pan-Asia Trial Problem; Mitsubishi Tanabe Tries To Rebound From Earthquake: Japanese Earnings Roundup (Part 1)

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Dainippon Sumitomo Pharma Co. Ltd. has a lot riding on anticipated blockbuster Latuda (lurasidone); for the 2011 fiscal year, the company forecasts sales will plunge 4.6% to ¥362 billion due to sales decreases in its major products. Such is the importance of the schizophrenia drug that the company announced during its May 12 full-year earnings call a post-Latuda strategy, even though the schizophrenia drug just launched in the U.S. in February

You may also be interested in...



Success Hinging On Single Platforms For Kissei, Dainippon Sumitomo, NanoCarrier and Eisai: Japan Earnings Roundup (Part 2)

A look at key products that could determine the year ahead for Japanese pharma.

Astellas Awaiting Safety Data For Mirabegron; Expects To File NDA In U.S. In Q2

TOKYO - Astellas provided an update on development for blockbuster-hopeful mirabegron, and the main theme of its progress appears to be safety, or rather waiting for safety data. The company delayed U.S. and EU filings for the drug on regulatory requests for more safety data to assess cardiovascular risk. The company rescheduled mirabegron's FDA filing for 2Q/FY2011, and now everyone is waiting for full results on additional safety studies

Astellas Awaiting Safety Data For Mirabegron; Expects To File NDA In U.S. In Q2

TOKYO - Astellas provided an update on development for blockbuster-hopeful mirabegron, and the main theme of its progress appears to be safety, or rather waiting for safety data. The company delayed U.S. and EU filings for the drug on regulatory requests for more safety data to assess cardiovascular risk. The company rescheduled mirabegron's FDA filing for 2Q/FY2011, and now everyone is waiting for full results on additional safety studies

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel